Request Information
Request Information
Nov 29 2018
Auris was featured on Compelo, a online news publication covering medical devices, about additional funding received to advance the Monarch Platform.
Continue ReadingNov 28 2018
Auris Health is featured in Xconomy for its recent round of fundraising. Auris Health was able to raise an additional $220 million in funding to further bolster its commercialization efforts. Auris received clearance from the FDA to sell the first robotic bronchoscope offered on the Monarch Platform.
Continue ReadingNov 15 2018
November is Lung Cancer Awareness Month (LCAM). Auris is proud to raise awareness and support the education of lung cancer, a disease that kills more people than breast, colon and prostate cancer combined. Throughout the month on our social media, we share articles and interviews on lung cancer research and promote lung cancer survivor stories. View our infographic to learn quick facts of this deadly disease and the evolution of biopsy methods overs the years.
Oct 30 2018
CHICAGO (Ivanhoe Newswire) - Lung cancer kills more Americans than breast, prostate and colon cancer combined, and like other forms of cancer, the earlier it’s caught, the better chance patients have to survive. Now, a new device is helping doctors diagnose lung cancer in one minimally-invasive procedure.
Continue ReadingOct 22 2018
Massdevice features Auris Health’s ACCESS study results, which were first announced at CHEST 2018 in San Antonio, Texas by Dr. Alexander Chen from Washington University in St. Louis. This study was the follow-up to the REACH study, which focused on the Monarch Platform’s ability to reach deeper into the lung’s periphery. With the ACCESS study, eight investigators performed robotic-assisted procedures using the Monarch Platform on a cadaveric model designed to mimic a real-life bronchoscopy procedure.
Continue ReadingOct 11 2018
Dr Kyle Bramley is interviewed at CHEST about the study presented at CHEST by Alex Chen, M.D. on robotic assisted bronchscopic biopsy of peripheral pulmonary lesions in a cadaveric model with simulated tumor targets.
Continue ReadingOct 08 2018
Auris Health, Inc. announced the results of the Nodule Access study at the CHEST 2018 Annual Meeting in San Antonio. Alexander C. Chen, M.D., Director of Interventional Pulmonology at Washington University of St. Louis, shared the findings during the Late-Breaking Abstract session.
Continue ReadingJun 01 2018
Auris Health made the coveted CNBC Disruptor 50 List for 2018, making it one of the few healthcare companies to receive the honor. Each year CNBC features private companies of all types whose game-changing innovations are transforming how the world does business. Joining the ranks of Airbnb, Lyft, and SpaceX, Auris was honored for the innovative work it brings to bronchoscopic procedures with its Monarch Platform. The goal of Auris’s robotic technology is to enable more accurate diagnosis, and eventually treatment, of small and hard-to-reach nodules in the periphery of the lung.
Continue ReadingMay 15 2018
Auris announced its collaboration with NeuWave Medical, a subsidiary of Ethicon, Inc. and part of the Johnson & Johnson Medical Devices Companies this week. The goal is to enable robotically assisted bronchoscopic ablation of lesions in the lung. This cooperative development and commercialization agreement calls for a co-development of integrated systems for robotic control, navigation and application of microwave ablation delivered via bronchoscopes.
Continue ReadingApr 12 2018
Dr. Frederic Moll, CEO of Auris Health was featured in The Wall Street Journal in an article about Auris and its innovative technologies. Dr. Moll, a serial entrepreneur and surgical robotics visionary, helped pioneer Auris’s beginnings and has pushed for medical innovation for over 30 years. He co-founded his first start-up, Endotherapeutics Corp., in the 1980s, developing products for laparoscopic or minimally invasive surgery. Gil Kliman, an investor in Restoration Robotics (another one of Dr. Moll’s ventures), said of Dr. Moll’s drive for success: “He is the one human that will never be replaced by a robot. He won’t give up on things; he can push though the inevitable naysayers.”
Continue ReadingBronchoscopy:
Complications from bronchoscopy are rare and most often minor, but if they occur, may include breathing difficulty, vocal cord spasm, hoarseness, slight fever, vomiting, dizziness, bronchial spasm, infection, low blood oxygen, bleeding from biopsied site, or an allergic reaction to medications. Only rarely do patients experience other more serious complications (for example, collapsed lung, respiratory failure, heart attack and/or cardiac arrhythmia).
Urology:
Adverse effects from both Mini-PCNL and Ureteroscopy include pain, urinary tract infection, fever, hematuria (presence of blood in urine), exposure to low levels of radiation, retained or residual stones.
Adverse effects from ureteroscopy may include pain, perforation or injury to the ureter, resulting in extravasation of fluid and urine (urinoma), stricture of the ureter with risk of subsequent obstruction (hydronephrosis needing further repair), rare avulsion of the ureter, urinary blood clots, residual stones.
PCNL access may result in minor and major adverse effects. Minor effects include fever and nephrostomy leak. Major adverse effects may include injuries to pleura, liver, spleen, large vessels with related bleeding, gallbladder, duodenum, jejunum, colon with related cutaneous fistula, fever, pain, ileus, elevated counts.
Major adverse effects related to stone removal may include infection and urosepsis, intravascular fluid overload, extravasation of fluid, and post percutaneous nephrolithotomy bleeding.